Enicepatide
CT-388 · RO7795068 · Roche
Once-weekly GLP-1/GIP dual agonist in Phase 3 weight-management trials.
Selected study results
CT-388-103Placebo-adjusted weight-loss differencePlacebo-adjusted weight-loss difference: −22.5 percentage points · 48 weeks · Phase 2
Placebo-adjusted weight-loss difference · 48 weeks
Study focus: Weight management without type 2 diabetes
Placebo-adjusted difference, not the total change in the active arm.
Placebo-adjusted difference. Treatment-regimen difference was 18.3 percentage points.
Adults with obesity/overweight and a complication, without type 2 diabetes · 24 mg weekly after escalation · Trial N=469 · Efficacy estimand; sponsor topline. Results & methods ↗
CT-388-104Mean body-weight reductionBody weight decreased 15.5% · 48 weeks · Phase 2
Mean body-weight reduction · 48 weeks
Study focus: Weight management with type 2 diabetes
Adults with type 2 diabetes and obesity/overweight · Enicepatide 24 mg weekly · Trial N=447 · Sponsor topline; placebo weight result and estimand not given. Results & methods ↗
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: ENITH-1/2 Phase 3 weight-management trials ongoing; Phase 2 T2D/obesity topline released September 22.
Next: Full Phase 2 results and subsequent development updates; the CT-388-104 registry is completed.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies2 records
ENITH-1
Weight managementAdults with obesity or overweight without type 2 diabetes; global weight-management study.
ENITH-2
Weight management with type 2 diabetesAdults with obesity or overweight and type 2 diabetes; global weight-management study.
Phase 2 studies2 records
CT-388-103
Weight management48-week study in adults with obesity or overweight and at least one weight-related comorbidity; without type 2 diabetes. Published/sponsor results are shown in the evidence section.
CT-388-104
Weight management with type 2 diabetes48-week study in adults with obesity or overweight and type 2 diabetes; separate from CT-388-103.
